OssDsign announced the CEO transition is planned for H2/25, where Morten Henneveld will step down at end-2025. Its aim is to establish leadership, with an even stronger presence in and focus on the US market where OssDsign has 100% of net sales. Mr. Henneveld has been instrumental in transitioning OssDsign from an EU cranial patient-specific implant company to a US-focused orthobiologics company with scaling opportunities. We see no drama and agree with the US importance.
LÄS MER
